Navigation Links
Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
Date:9/12/2007

Pharmacopeia Elects to Expand Study to Include 1,000 mg Dose

PRINCETON, N.J., Sept. 12 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced that based on initial results from the Company's Phase 1 multiple ascending dose (MAD) study of its lead internal product candidate, PS433540 (DARA), no safety or tolerability issues were observed with any of the doses under evaluation. As a result, the study will be expanded to include a 1,000 mg dose. This study designed to evaluate 14 days of daily dosing in healthy volunteers, has already completed evaluation of 50, 100, 250 and 500 mg doses of PS433540. The Company expects to report findings from the 1,000 mg dose later this year.

"The purpose of a multiple ascending dose study of this nature is to determine the maximally tolerated dose of a compound in healthy volunteers. Since we did not reach that threshold with this study's original four doses, we've decided to expand the trial and evaluate this fifth dose level," stated Rene Belder, M.D., Pharmacopeia's Vice President of Clinical and Regulatory Affairs. "The fact that this compound appears safe and well tolerated at a wide dose range will provide added dosing flexibility for subsequent clinical trials."

In addition, results from the initial Phase 1 trial of PS433540, a single ascending dose (SAD) study, indicated that the compound was well tolerated at all six doses administered, while also suggesting that PS433540 possesses a half-life that is consistent with once daily oral administration.

PS433540 is a dual-acting angiotensin (AII) and endothelin (ET1) receptor antagonist that is being dev
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... WALTHAM, Mass., Dec. 3 Decision...d advisory firms focusing on pharmaceutical and he...s drug market in Brazil will grow from $417 millio...5 percent annual growth rate is attributed to a gr...ased use of new generation antidiabetics such as M...
(Date:12/3/2009)...ELZE, Germany, Dec. 3 Honeywell (N...tion agreement with Pro-Lab Laboratuar Teknolojile...; Jackson® high-purity solvents in Turkey. ,...ively by biotechnology and pharmaceutical companie..., "The annual growth rate of the Turkish pharmac...
(Date:12/3/2009)...ERSUSALEM and NEEDHAM, Massachusetts, December 3 /... Swiss Exchange: ORIDN) today announced that the B...capnographs for its RTW (Rettungswagen) medical ve...teams to assess the ventilation status of a patien...iratory status such as displaced endotracheal tube...
Breaking Medicine Technology:Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 2Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 3Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 2Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 3Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety 4Gene Discovery Gives Clues to Crohns Disease Colitis 60715 1Gene Discovery Gives Clues to Crohns Disease Colitis 60715 2Gene Discovery Gives Clues to Crohns Disease Colitis 60715 3Nationally Known Psychotherapist Dr Robi Ludwig Joins Qualsecs Wholly Owned Subsidiary VitaminSpice 60711 1Nationally Known Psychotherapist Dr Robi Ludwig Joins Qualsecs Wholly Owned Subsidiary VitaminSpice 60711 2Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 1Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 2Regence Foundation Announces Largest Set of Quarterly Grant Awards in Its History 60707 3
..., May 29 GlaxoSmithKline [NYSE: GSK] and Genmab ...tes Food and Drug Administration,s (FDA) Oncologic... that the ARZERRA(TM) (ofatumumab) data are reason...ts with chronic lymphocytic leukemia (CLL) whose d...b. Ofatumumab is an investigational treatment. , ...
... Perceptive Informatics, the industry,s leading e...REXEL International Corporation (Nasdaq: PRXL ),...to help investigators apply the new 1.1 version of...ors) in medical imaging-based oncology trials. Per...n the RECIST Working Group, has incorporated into ...
Other Medicine Technology:FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 2FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 3FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 4FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (ofatumumab) 5Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials 2Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials 3Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials 4Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials 5
(Date:12/3/2009)...ng in the livers of primates , , , THUR...at hepatitis C has shown promise in a primate stud...egy to prevent the hepatitis C virus from replicat... itself, the new DNA-based drug targets a small RN...replicate, the researchers explained. , By inhi...
(Date:12/3/2009)...IPPANY, N.J. and ANDOVER, Mass., Dec. 3 /PRNewswir...ntelligence® company, and Visage Imaging®...td. (ASX: PME) announced today that they have ente...et advanced oncology solutions for the clinical an...p enables Definiens to utilize the Visage® CS...
(Date:12/3/2009)...wswire-USNewswire/ -- A recent study conducted by ...tners HealthCare, found that text messaging is an ...the daily use of sunscreen, and this technology ma...lic health initiatives. Study participants who rec...were nearly twice as adherent to applying sunscree...
(Date:12/3/2009)...cases created by a single case of H1N1 influenza i...ation, social distancing and the use of antiviral ...irus, suggests an epidemiological modelling study ...eported in CMAJ ( Canadian Medical Association ...data from laboratory-confirmed cases of H1N1 betwe...
(Date:12/3/2009)...en the heart is stopped and restarted, the patient...anently damaged. Therapeutic hypothermia, a treatm...ered and maintained several degrees below normal f...ese harmful effects and improve survival in adults...udy of its kind, physician-scientists are evaluati...
Breaking Medicine News(10 mins):Health News:New Hepatitis C Treatment Shows Promise 2Health News:New Hepatitis C Treatment Shows Promise 3Health News:Visage Imaging and Definiens Announce Partnership 2Health News:Visage Imaging and Definiens Announce Partnership 3Health News:Cell Phone Text Messaging Technology is a Low-Cost, Effective Way to Improve Use of Sunscreen and Reduce Risk of Skin Cancer, According to a New Study 2Health News:Cell Phone Text Messaging Technology is a Low-Cost, Effective Way to Improve Use of Sunscreen and Reduce Risk of Skin Cancer, According to a New Study 3Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Cooling may benefit children after cardiac arrest 2
...ll players have known for more than a hundred year... , At the fifth annual international Best Visual ...a mind-boggling entry called "The Break of the Cur...ct the movement of a spinning disk. The illusion ...
...nts living with migraine have strong reason for ne...w articles and an accompanying editorial, "The Fut... current issue of Mayo Clinic Proceedings, are the...and society," according to the editorial written b...
...Will Perpetuate Role of Supreme Court as "National... Americans United for Life (AUL) President &...ack Obama nominating Sonia Sotomayor to replace Ju...ntradicts that hollow promise. Judge Sonia Sotoma...
...lvania is partnering with schools to reduce childh...d longer life, Secretary of Health Everette James ...ced today. , , James and Zahorchak visited Albert... students. , , "The prevalence of obesity among ...
...tive Reproductive Resources ( ARR ) today announ...avoid some of the pitfalls of "do-it-yourself" ges...anagement Services , the Chicago egg donation and...ely to be equipped to handle on their own. , , "W...
...rbohydrates, regardless of weight loss, appears to...an animal study being published this week by resea...ork here and elsewhere has shown that a diet light...ount of energy feeding tumors, we weren,t able to ...
Other Medicine News:Health News:'Curve ball' wins international illusion contest 2Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 2Health News:Mayo Clinic Proceedings: The Evolution of Migraine from Episodic Headache to Chronic Disorder 3Health News:Americans United for Life: Obama Nominates Avowed Judicial Activist Judge Who Undermines Common Ground 2Health News:Pennsylvania Secretaries of Health, Education Announce New Grant Initiatives to Curb Childhood Obesity, Boost Physical Activity in Schools 2Health News:New Program Offsets Risks of 'Do-It-Yourself' Gestational Surrogacy 2Health News:Carbohydrate restriction may slow prostate tumor growth 2
...Fill2 is the ideal system for fast, accurate filli...pinch valve controlled dispensing mechanism, ensur... of the components that come into contact with the...oclave. The unique compact design saves valuable b...
...Fill2 is the ideal system for fast, accurate filli...pinch valve controlled dispensing mechanism, ensur... of the components that come into contact with the...oclave. The unique compact design saves valuable b...
...Fill2 is the ideal system for fast, accurate filli...pinch valve controlled dispensing mechanism, ensur... of the components that come into contact with the...oclave. The unique compact design saves valuable b...
...atic dispenser for low volumes. Dispenses volumes ...throughput of less than 30 seconds per plate signi...ures an intuitive user interface that provides one...uids and suspensions, beads, or cells, with high p...
Medicine Products: